In 40 patients with ASPS and a rearrangement of the TFE3 gene treated with the serine/threonine-protein kinase Haspin homolog ALK1 and hepatocyte growth factor receptor (MET) inhibitor crizotinib, one patient had a partial response and 35 had stable disease as their best response, with 1-year progression-free survival of 37·5% (95% CI 22·9–52·1).14 This evidence concerns the gene MET and alveolar soft part sarcoma.